



# Catalytic Asymmetric Synthesis of Meta Benzene Isosteres—Nortricyclane

Reporter: Zefang Jin

2025/01/18




# Benzene Ring in Medicinal Chemistry




# Benzene Ring in Medicinal Chemistry



## Solubility concern:



## Lipophilicity concern:




## Metabolic stability and safety concern:




# Benzene Ring in Medicinal Chemistry


## a Bioisosteres for *para*-substituted benzene



## b Potential isosteres for *ortho*-substituted benzene




## c Potential isosteres for *meta*-substituted benzene



# Tricyclo[2.2.1.0<sup>2,6</sup>]Heptane (Nortricyclane)




Meta arene




Nortricyclane


Atom distance ( $d$ )	2.4 Å	2.4 Å
Exit vector angle ( $\theta$ )	120°	127°
Dihedral angle	0°	2°




**13**, (+)- $\alpha$ -santlene



**14**, cyclosinularane




**15**, cyclomylytalan-5 $\alpha$ -ol




**16**, longicyclene

*Org. Biomol. Chem.* **2019**, 17(18): 4456-4459.



*Chem. Ind.* **1956**: 56-57.



*J. Am. Chem. Soc.* **1963**, 85: 1019-1020.



# James P. Morken

- Professor of Chemistry
- Louise and Jim Vanderslice and Family Chair

## Experience


- 1985—1989, B.S., University of California at Santa Barbara (Advisor: Bruce Rickborn)
- 1990—1995, Ph.D., Boston College, (Advisor: Amir H. Hoveyda)
- 1995—1997, Postdoc, Harvard University, (Advisor: Stuart L. Schreiber)
- 1997—2002, University of North Carolina at Chapel Hill, Assistant Professor
- 2002—2006, University of North Carolina at Chapel Hill, Associate Professor;
- 2006-2007, Boston College, Professor of Chemistry;

## Selected Honors and Awards

- Arthur C. Cope Scholar Award, 2018
- Sloan Foundation Fellow, 2004-2006
- David and Lucile Packard Foundation Fellow, 1998-2003
- Bristol-Myers Squibb Award, 2002


# Diboration of Alkenes

## 1. Diboration of Allene




*J. Am. Chem. Soc.* **2004**, 126, 50: 16328-16329.

## 2. Diboration of Conjugated-Dienes




*J. Am. Chem. Soc.* **2009**, 131, 26: 9134-9135.

## 3. Diboration of Terminal Alkyne



*Nature*, **2014**, 505: 386-390.





$L_1$ :  $R_1 = \text{H}$ ,  $R_2 = \text{NMe}_2$


$L_2$ :  $R_1 = \text{Me}$ ,  $R_2 = \text{Ph}$

$L_3$ :  $R_1 = \text{i-Pr}$ ,  $R_2 = \text{Ph}$

# Tricyclo[2.2.1.0<sup>2,6</sup>]Heptane (Nortricyclane)




*Chem. Ind.* **1956**: 56–57.


























*J. Am. Chem. Soc.* **1963**, 85: 1019–1020.

This work






# Ligand Screening





# Conditions Screening




entry	variants	NMR y.(%)	er	RSM(%)	entry	variants	NMR y.(%)	er	RSM(%)
1	none	89.6	94:6	-	13	Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, dioxane, rt	71.2	90:10	-
2	KF	90.8	93:7	-	14	Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, MTBE, rt	< 5	nd	94.2
3	KOH	91.4	89:11	-	15	PdCl <sub>2</sub> , Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	55.9	96.4:3.6	28.0
4	K <sub>2</sub> CO <sub>3</sub>	93.3	96:4	-	16	Pd <sub>2</sub> (dba) <sub>3</sub> , Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	81.3	96.7:3.3	-
5	KOAc	84.2	91:9	-	17	Pd-G3, Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	94.2	96.6:3.4	-
6	K <sub>2</sub> CO <sub>3</sub> , rt	88.6	96.1:3.9	-	18	1.5 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	79.3	96.9:3.1	-
7	Na <sub>2</sub> CO <sub>3</sub> , rt	87.4	96.4:3.6	-	19	3 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	83.9	96.3:3.7	-
8	Cs <sub>2</sub> CO <sub>3</sub> , rt	88.9	95.7:4.3	-	20	5 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	78.8	96.2:3.8	-
9	K <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, rt	79.2	96.8:3.2	-	21	1.5 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, 9:1 THF/H <sub>2</sub> O, rt	99.5	97.1:2.9	-
10	Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, ACN, rt	66.3	87:13	21.9	22	1.5 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, 1:2 THF/H <sub>2</sub> O, rt	70.3	95:5	-
11	Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, toluene, rt	39.1	95:5	53.7	23	1.5 eq. Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, no H <sub>2</sub> O, rt	< 5	nd	101.1
12	Na <sub>2</sub> CO <sub>3</sub> , 3% (S,S)-L1, 2-MeTHF, rt	67.5	97.6:2.4	37.9					


# Substrate Expansion




**32**, (r.t., 14 h)  
97% y., 97:3 er




**33**, (r.t., 14 h)  
96% y., 85:15 er




**34**, (60°C, 14 h)  
95% y., 96:4 er




**35**, (60°C, 14 h)  
94% y., 94:6 er




**36**, (r.t., 14 h)  
95% y., 95:5 er




**37**, (60°C, 14 h)  
92% y., 90:10 er




**38**, (60°C, 14 h)  
95% y., 98:2 er




**39**, (60°C, 14 h)  
56% y., 70:30 er




**40**, (60°C, 14 h)  
93% y., 97:3 er




**41**, (0°C, 14 h)  
96% y., 75:25 er



**42**, (r.t., 14 h)  
96% y., 93:7 er




**43**, (60°C, 14 h)  
62% y., 89:11 er




**44**, (r.t., 14 h)  
83% y., 97:3 er




**45**, (60°C, 14 h)  
94% y., 95:5 er




**46**, (r.t., 24 h)  
77% y., 87:13 er




**47**, (60°C, 14 h)  
84% y., 96:4 er



**48**, (60°C, 24 h)  
94% y., 98:2 er





**49**, (60°C, 14 h)  
72% y., 69:31 er











**50**, (60°C, 14 h)  
56% y., 66:34 er

# Challenging Substrates Expansion




# Substrate Synthesis and Subsequent Derivatization




# Mechanism Study

## DFT Calculation




# Mechanism Study


## $^{13}\text{C}$ Kinetic Isotope Effects




KIE Values on Each Carbon



## Calculated Stereochemistry-Determining Transition States






**TS1a**  
Favoured  
 $\Delta G^\ddagger = 0.7 \text{ kcal mol}^{-1}$




**TS1a'**  
Disfavoured  
 $\Delta G^\ddagger = 3.7 \text{ kcal mol}^{-1}$


# Biophysical and Biochemical Properties



URB597, 78



(3R,5S)-79




(3S,5R)-79


	URB597	(3S,5R)-79	(3R,5S)-79
MW (g/mol)	338.4	354.4	354.4
Kinetic solubility (μM)	1.01	12.66	10.16
α log D	3.69	3.57	3.56
Microsomal stability(% remaining)	37	67	75
IC <sub>50</sub> FAAH (μM)	0.0114	0.5	> 4



# Biophysical and Biochemical Properties




	Sonidegib (3S,5R)-81 (3R,5S)-81		
MW (g/mol)	485.5	487.5	487.5
Kinetic solubility ( $\mu\text{M}$ )	0.02	1.04	0.86
$\alpha$ log D	5.74	5.62	5.61
Microsomal stability(% remaining)	78	31	50
IC <sub>50</sub> Hh ( $\mu\text{M}$ )	0.0036	0.5	0.2




# Summary

## 1. Efficient, enantioselective, catalytic synthesis of Neotricyclane



## 2. Significant improvement in drug solubility



Thanks for your attention!